Be interesting to see the future trend, (over the next month) if the selling ‘has’ finished, I wonder if the inquiry (findings still to be announced/ref to the unusual trading) had a impact on that?, or mission accomplished by the seller.
No announcement by the company on this matter would certainly be remiss in view of the sp being discounted by a massive 35% plus in a month period THIS despite the glowing feedback from the current IP.
There was no rerate on the last deal and certainly nothing priced into the current sp on the potential of the current IP.
I think for a rerate a 40 mill plus deal must be on the cards, that would give the company plenty of time to consolidate itself until such time the finding of the clinical results are announced.
Ann: Unusual Trading Patterns, page-90
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$9.91 |
Change
-0.090(0.90%) |
Mkt cap ! $209.4M | |||
| Open | High | Low | Value | Volume |
| $10.00 | $10.00 | $9.65 | $70.76K | 7.202K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $9.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $9.91 | 475 | 2 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |